FDA Approved Drug Targeting Changes In Solid Cancers
In a first ever instance, the FDA has granted accelerated approval to pembrolizumab (Keytruda), a cancer drug that could benefit patients with DNA abnormalities such MSI-H and dMMR, notwithstanding the location of the tumor in the body. The safety and efficacy of Pembrolizumab were assessed in patients with solid tumors having MSI-H or dMMR enrolled in one of five single-arm clinical, uncontrolled trials.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer